The role of SGLT2 inhibitors in cardiorenal protection: state of the art.
Thursday 27th January 2022
6.00PM CET (5.00PM UK time)
This activity has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 1 European CME credits (ECMEC®s)*
In this meeting we revisit the latest evidence on secondary preventive effect of SGLT2 inhibitor drugs.
The key learning objectives will be:
- To discuss the cardioprotective effects of SGLT2 inhibitors in terms of heart failure.
- To discuss the effect of SGLT2 inhibitors on kidney function
PCDE Talks are interactive sessions. You will have the opportunity to submit your questions to the chair by chat throughout the webinar. The last part of the webinar will be dedicated to discussion and Q&A’s.
Dr. Samuel Seidu, MBChB, PGCME, MSc, MD, FRCGP, FRCP (Edin)
NIHR Clinical Lecturer University of Leicester.
Chair of Study Group for Primary Care Diabetes Europe
Heart failure and SGLT2 inhibitor therapy beyond the presence of diabetes
Dr. Xavier Garcia-Moll. Cardiologist, MD, FESC, FACC.
Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-interna-tional-activities.
Live educational activities, occurring outside of Canada, recognised by the UEMS-EACC-ME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada
Copyright © 2021 Primary Care Diabetes Europe (PCDE), All rights reserved.
Our address is:
Primary Care Diabetes Europe (PCDE) · Bredestraat 79 · Ekeren 2180 · Belgium